A phase 3 clinical trial finds an anti-inflammatory drug used in rheumatoid arthritis can preserve lung function in patients with systemic sclerosis.
Osteopontin is discovered as the culprit behind these patients’ main cause of death. However, a repurposed immunosuppressive drug may combat the pro-inflammatory protein.
By studying the roles of an inflammatory protein and antibodies in chronic rejection after lung transplantation, researchers discover possibilities for new treatments.
The lung stiffness and scarring characteristic of this rare disease may be linked to environmental gene alterations.
Under development at C.S. Mott Children’s Hospital, the pediatric artificial lung could offer new hope for treating children with lung failure.